ライフサイエンスコーパス: type 2

1 d obesity and diabetes diagnoses (Type 1 and Type 2).

2 ct dUTPases, Dut80alpha (type 1) and DutNM1 (type 2).

3 acioscapulohumeral muscular dystrophy (FSHD) type 2.

4 ycling proteins including ryanodine receptor type 2.

5 er human 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2).

6 OCDO) by 11beta-hydroxysteroid-dehydrogenase-type-2 (11betaHSD2).

7 tA F3-6), except 2, which had different PorB types (2-78 and 2-52).

8 Vectors based on adeno-associated virus type 2 (AAV2) are powerful tools for gene transfer and g

9 o suppress lymphadenopathy and T helper cell type 2 activation.

10 ance in the pathogenesis of allergen-induced type 2 airway inflammation and identify cellular sources

11 stic feature of asthma, produces spontaneous type 2 airway inflammation in juvenile beta-epithelial N

12 rhinovirus infection and the exacerbation of type-2 allergic inflammation in humans.

13 either in severe AME or a milder phenotype (type 2 AME).

14 te that circulates at high concentrations in type 2 and gestational diabetes patients.

15 d TSLP, resulting in increased production of type 2 and other proinflammatory cytokines.

16 on levels of 17 genes characterizing type 1, type 2, and type 17 lymphocytes were measured in sputum

17 mmation, mucus-secreting cell (MSC) numbers, type 2-associated cytokines (interleukin (IL)-33, thymic

18 d MDSC were expressed C-C chemokine receptor type 2 (CCR2), which was enhanced by exposure to interfe

19 CD4(+) T cells into tumor-promoting T helper type 2 cell (Th2 cell), Th17 cell, and regulatory T cell

20 rostaglandin D2, and eosinophil and T-helper type 2 cell chemokines compared with healthy subjects.

21 ding cellular and molecular understanding of type-2-cell-mediated immunity, as well as new areas such

22 report the generation of alveolar epithelial type 2 cells (AEC2s), the facultative progenitors of lun

23 his study, we tested the ability of cGMP and type 2 cGMP-dependent protein kinase (PKG2) to activate

24 er, cervical dysplasia, herpes simplex virus type 2, chlamydia, and syphilis.

25 c organisms, as well as Retinitis Pigmentosa Type 2-Clathrin Light Chain, a membrane protein with a n

26 n shown to cause Charcot Marie Tooth Disease type 2 (CMT-2) or distal hereditary motor neuropathy (dH

27 erferon regulatory factor 4-dependent dermal type 2 conventional DC subsets and not by epidermal Lang

28 n of corticotropin-releasing factor receptor type 2 (CRFR2) to be associated with post-traumatic stre

29 nterleukin (IL)-13 is a pleiotropic T helper type 2 cytokine frequently associated with asthma and at

30 plasia, accumulation of ILC2s and TH2 cells, type 2 cytokine production, and airway hyperresponsivene

31 FH cell numbers and IgE antibody levels, but type 2 cytokine responses and eosinophilic inflammation

32 ignificant inverse associations with several type 2 cytokine responses.

33 ased on disrupting allergic inflammatory and type 2 cytokine-mediated responses, including anti-cytok

34 imulation of the thymic microenvironment via type 2 cytokines from innate T cells.

35 on liver tissue damage through expression of type 2 cytokines thereby participating in the pathogenes

36 were also collected and levels of IL-33 and type 2 cytokines were measured.

37 roup 2 innate lymphoid cells (ILC2s) produce type 2 cytokines, and although advances have been made i

38 SA was used to assess the production of IgE, type 2 cytokines, and Ccl24.

39 he response to ozone, including increases in type 2 cytokines.

40 at single-nucleotide resolution for the I-A type 2'dG-sensing riboswitch from Mesoplasma florum by N

41 -12)), ulcerative colitis (P<1.0 x 10(-20)), type 2 diabetes (P=2.8 x 10(-13)), hip/waist circumferen

42 dy mass index (P=2.2x10(-5)) and the risk of type 2 diabetes (P=6.1x10(-4)) associated with the risk

43 Although a large proportion of patients with type 2 diabetes (T2D) accumulate misfolded aggregates co

44 cated hemoglobin (HbA1c) is used to diagnose type 2 diabetes (T2D) and assess glycemic control in pat

45 Obesity and associated type 2 diabetes (T2D) are important risk factors for inf

46 change in islet mass in different stages of type 2 diabetes (T2D) as measured by noninvasive imaging

47 Type 2 diabetes (T2D) has attained the status of a globa

48 Type 2 diabetes (T2D) has many cardiovascular complicati

49 f a combination of fatty acids with incident type 2 diabetes (T2D) has not been evaluated.

50 ew genome-wide association studies (GWAS) of type 2 diabetes (T2D) have been conducted in U.S Hispani

51 isk in cohort studies, while the relation to type 2 diabetes (T2D) in the elderly remains unclear.

52 x hormones (ESH) are associated with risk of type 2 diabetes (T2D) in women.

53 The effect of Copy Number Variants (CNVs) on Type 2 Diabetes (T2D) remains little explored.

54 GLP-1) receptor (GLP-1R) is a key target for type 2 diabetes (T2D) treatment.

55 beta-Cell failure in type 2 diabetes (T2D) was recently proposed to involve d

56 polypeptide (IAPP), which is associated with type 2 diabetes (T2D), with the Alzheimer's disease amyl

57 uconeogenesis is also a signature feature of type 2 diabetes (T2D).

58 ects with classical and early-onset forms of type 2 diabetes (T2D).

59 n saturated fatty acids and the incidence of type 2 diabetes (T2D).A prospective cohort analysis of 3

60 glucose and plasma insulin in patients with type 2 diabetes (T2D).A randomized crossover clinical tr

61 reduction of macrovascular complications in type 2 diabetes (T2D); however, the underlying mechanism

62 anagement of hyperglycaemia in patients with type 2 diabetes admitted to general medicine and surgery

63 ased drugs in the treatment of patients with type 2 diabetes admitted to hospital has not been extens

64 ariants associated with an increased risk of type 2 diabetes affect the function of a monocarboxylate

65 ed end point trial, consenting patients with type 2 diabetes aged >18 years, with waist circumference

66 For example, some hypertension and type 2 diabetes alleles will be associated with BMI in s

67 Young-onset type 2 diabetes also affects more individuals of working

68 The incidences of both type 1 and type 2 diabetes among youths increased significantly in

69 RPRETATION: In a population of patients with type 2 diabetes and a broad cardiovascular risk profile,

70 SA, enrolling patients aged 18-80 years with type 2 diabetes and a random blood glucose concentration

71 usions In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular d

72 reased in skeletal muscle from patients with type 2 diabetes and are decreased following endurance tr

73 ic component of obesity, insulin resistance, type 2 diabetes and associated morbidities.

74 flammation has been associated with incident type 2 diabetes and atherosclerotic cardiovascular disea

75 BMI), a measure of abdominal adiposity, with type 2 diabetes and CHD through the potential intermedia

76 ential association among these precursors of type 2 diabetes and cognitive dysfunction.

77 rns have been associated with lower risks of type 2 diabetes and coronary artery disease, but their r

78 abdominal adiposity has been associated with type 2 diabetes and coronary heart disease (CHD).

79 pants were selected based on the presence of type 2 diabetes and either prevalent CVD or CVD risk fac

80 de 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were re

81 beta-cells and down-regulated in type 1 and type 2 diabetes and in infiltrating activated immune cel

82 Type 2 diabetes and insulin resistance are associated wi

83 tion of arsenic exposure and metabolism with type 2 diabetes and insulin resistance.

84 utcomes of metformin use in populations with type 2 diabetes and moderate to severe chronic kidney di

85 ls of methionine and BCAAs, in patients with type 2 diabetes and NAFLD.

86 iflozin reduced albuminuria in patients with type 2 diabetes and prevalent albuminuria.

87 ns associated with Alzheimer's, Parkinson's, type 2 diabetes and prion diseases.

88 Cell phagocytosis is impaired in type 2 diabetes and requires RvE1 for activation.

89 Both type 1 and type 2 diabetes are associated with long-term complicati

90 ditions including heart disease, stroke, and type 2 diabetes are leading causes of preventable death.

91 Apolipoprotein E4 (E4) and type 2 diabetes are major risk factors for cognitive dec

92 Obesity and type 2 diabetes are significant risk factors for maligna

93 raglutide on renal outcomes in patients with type 2 diabetes are unknown.

94 ith exenatide to usual care in patients with type 2 diabetes are unknown.

95 Biomarkers for type 2 diabetes are useful for prediction and interventi

96 ng the patients in the surgery group who had type 2 diabetes at baseline, type 2 diabetes remitted in

97 We excluded participants with type 2 diabetes at baseline.

98 Among patients with type 2 diabetes at high risk for cardiovascular events,

99 proved HbA1c and bodyweight in patients with type 2 diabetes compared with placebo, and showed a simi

100 k individuals are twice as likely to develop type 2 diabetes compared with white individuals, and the

101 Because few insulin-treated patients with type 2 diabetes currently use CGM, these results support

102 Among adults with type 2 diabetes diagnosed for less than 10 years, a life

103 eing significantly associated with prevalent type 2 diabetes for participants with high dietary fat i

104 ypertension risks, using 3,448 patients with type 2 diabetes from the ADVANCE study (Action in Diabet

105 Finally, monocytes from patients with type 2 diabetes had increased Mll1 compared with control

106 cent obesity, an unprecedented phenomenon of type 2 diabetes has emerged in pediatrics.

107 Studies in animal models of type 2 diabetes have shown that glucagon-like peptide 1

108 Remission of type 2 diabetes is a practical target for primary care.

109 A hallmark of type 2 diabetes is impaired insulin receptor (IR) signal

110 Type 2 diabetes is often accompanied by dyslipidemia wit

111 Type 2 diabetes leads to premature death and reduced qua

112 Prevalence of type 2 diabetes mellitus (15.5%-5.9%), hypertension (29.

113 ividual CC lines were identified that showed type 2 diabetes mellitus (t2DM) development and signific

114 In type 2 diabetes mellitus (T2DM) patients (n = 38), the l

115 omising drug candidates for the treatment of Type 2 diabetes mellitus (T2DM).

116 ance leads to hyperglycemia, the hallmark of type 2 diabetes mellitus (T2DM).

117 lar morbidity and mortality in patients with type 2 diabetes mellitus and established cardiovascular

118 Patients with type 2 diabetes mellitus and prior cardiovascular events

119 Secretion of this hormone is dysregulated in type 2 diabetes mellitus but the mechanisms controlling

120 at baseline, of whom 67% had a diagnosis of type 2 diabetes mellitus for >10 years, 58% were receivi

121 in a post hoc analysis in 1147 patients with type 2 diabetes mellitus on hemodialysis who participate

122 flozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients).

123 ) randomly assigned 10 142 participants with type 2 diabetes mellitus to canagliflozin or placebo.

124 ease, spanning conditions such as obesity to type 2 diabetes mellitus with excess cardiovascular risk

125 ed a substantial proportion of patients with type 2 diabetes mellitus without clinically recognized e

126 nd adipokine abnormalities (the hallmarks of type 2 diabetes mellitus) are characteristic features of

127 ted States, including obesity, hypertension, type 2 diabetes mellitus, and cardiovascular disease.

128 preclinical candidates for the treatment of type 2 diabetes mellitus, as well as a promising startin

129 flozin on clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular dis

130 atic beta cell function underlies type 1 and type 2 diabetes mellitus.

131 uctose consumption in people with type 1 and type 2 diabetes mellitus.

132 ic therapy for hypertension in patients with Type 2 diabetes mellitus.

133 ences encountered by patients suffering from type 2 Diabetes Mellitus.

134 ugh overall still a rare disease, adolescent type 2 diabetes now poses major challenges to paediatric

135 were exclusively identified in the serum of type 2 diabetes patients.

136 current hyperglycemia and infection risk in type 2 diabetes patients.

137 We assessed the relative risk of type 2 diabetes prospectively for each cohort and lipid

138 mine the effectiveness of CGM in adults with type 2 diabetes receiving multiple daily injections of i

139 y group who had type 2 diabetes at baseline, type 2 diabetes remitted in 66 of 88 patients (75%) at 2

140 The treatment of type 2 diabetes requires positive modulation of GLP-1R t

141 Type 2 diabetes results from defects in both insulin sen

142 and environmental determinants of type 1 and type 2 diabetes risk and progression, as well as complic

143 arker were not significantly associated with type 2 diabetes risk overall (RR per interquintile range

144 cretion but has no evidence for an effect on type 2 diabetes risk.

145 In contrast, chronic hypertension and type 2 diabetes showed no significant associations.

146 1, 118 unique associations between published type 2 diabetes single nucleotide polymorphisms (SNPs) a

147 expression when compared to neutrophils from type 2 diabetes subjects.

148 LADA was more similar to type 2 diabetes than to type 1 diabetes.

149 ass-was associated with an increased risk of type 2 diabetes that intensified with increasing duratio

150 blood pressure, coronary artery disease, and type 2 diabetes using data from six independent GWAS con

151 The risk of type 2 diabetes was significantly greater during current

152 nicians prescribe metformin to patients with type 2 diabetes when pharmacologic therapy is needed to

153 th cognitive function in older patients with type 2 diabetes who are carriers of the haptoglobin (Hp)

154 e National Eye Center among 50 patients with type 2 diabetes with and without DR (n = 100 eyes).

155 meta-analysis of prospective cohort studies (type 2 diabetes), and a prospective cohort study (dental

156 416 patients aged >/=25 years with type 1 or type 2 diabetes, a serum creatinine (SCr) level of 1.3-3

157 and novel IAPP analogs for the management of type 2 diabetes, Alzheimer's disease, or other diseases

158 se measurements captured by individuals with type 2 diabetes, and against predictions generated by ex

159 ders and it tightly associates with obesity, type 2 diabetes, and cardiovascular disease.

160 n of this score with cardiometabolic traits, type 2 diabetes, and CHD was tested in a mendelian rando

161 py in reducing hyperglycemia in persons with type 2 diabetes, and has been associated with reduced mo

162 mplicated in the beta cells of patients with type 2 diabetes, and in the beta cells of obese diabetic

163 fic and tailored management of patients with type 2 diabetes, as has been shown in patients with matu

164 etitian as part of lifestyle intervention in type 2 diabetes, but further randomized studies are warr

165 ed by obesity, and are at risk of developing type 2 diabetes, cardiovascular disease and related meta

166 bolic multimorbidity (ie, at least two from: type 2 diabetes, coronary heart disease, and stroke) in

167 elopments in the diagnosis and management of type 2 diabetes, existing controversies, and future dire

168 After matching for age, sex, hypertension, type 2 diabetes, previous stroke, and anticoagulation, i

169 operties of metformin, a first-line drug for type 2 diabetes, remain elusive.

170 tty liver disease, hazardous alcohol use, or type 2 diabetes, reported higher prevalence of advanced

171 Aging is associated with increased risk for type 2 diabetes, resulting from reduced insulin sensitiv

172 production of sclerostin in mouse models of type 2 diabetes, suggest an endocrine function.

173 ght, obesity, smoking status, triglycerides, type 2 diabetes, waist-hip ratio, childhood cognitive ab

174 In this longitudinal study of patients with type 2 diabetes, we found no association between TZD use

175 present in more than 90% of individuals with type 2 diabetes, where it contributes to beta-cell apopt

176 To induce type 2 diabetes, wild-type (WT), p40IL-12(-/-) (p40(-/-)

177 In 1,259 type 2 diabetes-affected case subjects and 5,765 control

178 Type 2 diabetes-associated genetic loci were significant

179 m microvascular complications in adults with type 2 diabetes.

180 pectives in the pharmacological treatment of type 2 diabetes.

181 h as the prevention of metabolic syndrome or type 2 diabetes.

182 et diabetes of the young form 3 (MODY 3) and type 2 diabetes.

183 ociated with an increased risk of developing type 2 diabetes.

184 Of these patients, most (98%) had type 2 diabetes.

185 are increasingly being used as treatment for type 2 diabetes.

186 in fasting plasma insulin level and risk of type 2 diabetes.

187 x and lysosomal staining in human samples of type 2 diabetes.

188 ys is a relatively new strategy for treating type 2 diabetes.

189 ontribute to glucolipotoxicity that leads to type 2 diabetes.

190 ure of chronic disorders such as obesity and type 2 diabetes.

191 tion and may contribute to increased risk of type 2 diabetes.

192 ng disorder, cocaine addiction, obesity, and type 2 diabetes.

193 ways easy to distinguish LADA from type 1 or type 2 diabetes.

194 als with prediabetes who were diagnosed with type 2 diabetes.

195 er-2 inhibitor approved for the treatment of type 2 diabetes.

196 syndrome and 1.37 (1.03-1.82; P = 0.021) for type 2 diabetes.

197 ic lipid deposition, insulin resistance, and type 2 diabetes.

198 logs a useful and safe treatment modality in type 2 diabetes.

199 pression patterns of neutrophil receptors in type 2 diabetes.

200 5 as a potential target to prevent and treat type 2 diabetes.

201 over 2 y using MRI in overweight adults with type 2 diabetes.

202 y studied in persons with type 1 diabetes or type 2 diabetes.

203 pathway signaling in islets from donors with type 2 diabetes.

204 apine often induce excessive weight gain and type 2 diabetes.

205 sured in peripheral blood in the etiology of type 2 diabetes.

206 y yield insights into the pathophysiology of type 2 diabetes.

207 uld serve as potential drug targets to treat type 2 diabetes.

208 and PDR) with incident CVD in patients with type 2 diabetes.

209 enia is associated with an increased risk of type 2 diabetes.

210 s that enhance GLP-1 levels in patients with type 2 diabetes.

211 associated with a reduced risk of developing type 2 diabetes.We tested whether pomegranate polyphenol

212 ological treatment options are available for type 2 diabetes; however, many patients do not achieve o

213 ction against metabolic syndromes, including type 2 diabetes; however, mechanisms that are associated

214 le decreased risk of Parkinson's disease and type-2 diabetes and an increased risk of pregnancy loss.

215 Erythrocytes in patients with type-2 diabetes mellitus (T2DM) are associated with redu

216 a new drug target for insulin resistance in Type-2 diabetes, in which the unmet therapeutic need rem

217 importance for the treatment of obesity and type-2 diabetes.

218 n rescued angiogenesis and arteriogenesis in type 2 diabetic mice.

219 ies of non-diabetic and clinically diagnosed type 2 diabetic patients.

220 RDD and allodynia were present in type 1 and type 2 diabetic rats but not in rats with type 1 diabete

221 urves of glucose concentration of type 1 and type 2 diabetics were acquired at the Department of Endo

222 yeast), in vitro, and in vivo activities of type-2 diacylglycerol acyltransferases in Nannochloropsi

223 ted neuropathies such as Charcot-Marie-Tooth type-2, distal hereditary motor neuropathies, spinal mus

224 have been implicated in the pathogenesis of type 2-driven inflammatory human conditions.

225 Determination of type 1 and type 2 EBV in saliva samples from people from a wide ran

226 casian British people carrying predominantly type 2 EBV.

227 Multiple exposure to type 2 helper T cell (Th2)-inducing stimuli further enha

228 Insulin-like growth factor type 2 (IGF2) receptor (IGF2R) recognizes mannose 6-phos

229 IL-1Ra) and the decoy receptor IL-1 receptor type 2 (IL-1R2).

230 In particular, IL-5- and IL-13-producing type 2 ILCs (ILC2s) have been implicated in repair mecha

231 ymphoid cells (ILC2s) represent an important type 2 immune cell.

232 ificant increases in mRNAs associated with a type 2 immune response (interleukin [IL]5 gene, IL13, an

233 The type 2 immune response controls helminth infection and m

234 investigated whether genes associated with a type 2 immune response in the intestinal mucosa are up-r

235 g Tfh cells are central orchestrators of the type 2 immune response in the reactive lymph nodes durin

236 Current knowledge regarding type 2 immune responses in the lung are initially presen

237 Although the prominent role of TH2 cells in type 2 immune responses is well established, the newly i

238 pathways, leading to the development of the type 2 immune responses that characterize allergic disea

239 atinocyte differentiation defects and strong type 2 immune responses.

240 an induce, under some circumstances, mucosal type 2 immune responses.

241 ial role in protective as well as pathogenic type 2 immune responses.

242 ular matrix protein upregulated in asthma by type 2 immunity mediators.

243 he immune microenvironment to promote innate type 2 immunity, and also to integrate systemic metaboli

244 ll activation are necessary for induction of type 2 immunopathology and aspirin sensitivity.

245 or dexamethasone suppressed the magnitude of type 2 inflammation during a rhinovirus-induced acute ex

246 idence of activation of multiple pathways of type 2 inflammation in early life are at greatest risk f

247 s (ILC2s) expand in the lungs of mice during type 2 inflammation induced by the fungal allergen Alter

248 IL-33 is an instructive cytokine of type 2 inflammation whose expression is associated with

249 lymphoid cells (ILC2s) are key regulators of type 2 inflammatory responses.

250 Here, we describe type 2 innate lymphocytes (ILC2s) as a novel cell type r

251 Type 2 innate lymphoid cells (ILC2) share cytokine and t

252 es is well established, the newly identified type 2 innate lymphoid cells (ILC2s) can also contribute

253 using murine models of allogeneic BMT, that type 2 innate lymphoid cells (ILC2s) in the lower GI tra

254 Type 2 innate lymphoid cells (ILC2s) represent an import

255 Type 2 innate lymphoid cells (ILC2s) resemble TH2 cells

256 romotes cytokine (IL-5, IL-13) production by type 2 innate lymphoid cells (ILC2s).

257 Type 2 innate lymphoid cells and basophils were scarce i

258 hopoietin) by colon tissues, which activated type 2 innate lymphoid cells and dendritic cells to prom

259 creased the numbers of eosinophils, IL-13(+) type 2 innate lymphoid cells and IL-13(+)CD4(+) T cells

260 sed in airway epithelial cells, macrophages, type 2 innate lymphoid cells, and TH2 cells along with i

261 ed during tissue injury in sepsis, activates type 2 innate lymphoid cells, which promote polarization

262 c studies suggest the involvement of TH1 and type 2 interferon pathways.

263 Hig1 type 2 isoforms, which include the Rcf1 protein, are cha

264 nts with CCM, 9 (75%) had a single Zabramski type 2 lesion in a supratentorial location.

265 we also analysed data from long QT syndrome type 2 (LQT2) patients, testing the hypothesis that our

266 lity complex II/C-C motif chemokine receptor type 2) macrophages expressed higher levels of MerTK and

267 Multiple endocrine neoplasia type 2 (MEN 2) syndrome is an autosomal dominant, heredi

268 A type 2 metallothionein gene, SsMT2, was cloned from Suae

269 l characteristics among those with type 1 vs type 2 MIs, and the causes of type 2 MIs.

270 The number and proportion of type 1 vs type 2 MIs, demographic and clinical characteristics amo

271 with type 1 vs type 2 MIs, and the causes of type 2 MIs.

272 The distinct roles of type-1 and type-2 mutations suggest their potential utility in dise

273 explore risk stratification in patients with type 2 myocardial infarction and myocardial injury.

274 ss in noncardiovascular death, patients with type 2 myocardial infarction or myocardial injury have a

275 The majority of excess deaths in those with type 2 myocardial infarction or myocardial injury were b

276 g in individuals with NF type 1 (NF1) and NF type 2 (NF2), their pathogenic etiologies, and the ratio

277 ity and altered cytokine responses (enhanced type 2 or reduced virus-induced cytokine responses) from

278 polio vaccination campaign with a monovalent type 2 oral polio vaccine (mOPV2).

279 are resistant to infection with genotype 2 (type 2) porcine reproductive and respiratory syndrome vi

280 e checkpoint inhibitor molecule PD-L1 during type 2 pulmonary responses.

281 id system, and in particular the cannabinoid type 2 receptor (CB2R), raised the interest of many medi

282 e gB receptor the paired immunoglobulin-like type 2 receptor alpha (PILRalpha) than with gD receptors

283 or) and muscarinic (muscarinic acetylcholine type 2 receptor) receptors, and acetylcholinesterase act

284 nergic receptor, GABAB, or dopamine receptor type 2 receptors did not reveal any interaction between

285 ariables were examined, including markers of type 2-related inflammation and change in airway hyperre

286 Although type 2 responses are implicated in AD, emerging evidence

287 of an amplification system needed for local type 2 responses.

288 ets that comprise both primary and secondary type 2 responses.

289 Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant neurodegenerative

290 n two mouse models of spinocerebellar ataxia type 2 (SCA2), an autosomal dominant polyglutamine disea

291 sified into 2 groups: type 1 (classical) and type 2 (secondary) iSS.

292 3 and effects of genetic deletion of the key type 2 signal-transducing molecule signal transducer and

293 nhibition of fibroblast activation, T helper type 2-skewed immune polarization, M2 macrophage infiltr

294 odemographic variables, herpes simplex virus type-2 status, and recreational drug use.

295 tion might allow patient selection for novel type 2 therapeutics.

296 l enzyme 11beta-hydroxysteroid dehydrogenase type 2 to inactivate cortisol before it reaches the fetu

297 by ADAR2 (adenosine deaminase acting on RNA type 2) to transcripts in mammalian cells.

298 predictive value of tissue transglutaminase type 2 (tTG) antibodies performed with different kits bu

299 Vesicular monoamine transporter type 2 (VMAT2) imaging with PET allows assessment of the

300 1) highly recurrently mutated across sarcoma types; (2) within sarcoma types, genomic and regulomic d